Biotech

“I think one of the most exciting spaces at the moment is biotech and is the opportunity for young entrepreneurs who actually made those discoveries to actually be funded and be able to take those discoveries forward”

“In the past, you know, batch reading through applications, we've, we saw a lot of women applying with biotech companies and hardware, and you're seeing a pretty diverse range of companies come through”

“Particularly the earliest phase of discovery, that is an area where there's significant underinvestment just generally in the industry.”

“And we have so many great companies that are, like, in bio, I think we're gonna have some just giant exits, you know, 10 years from now.”

“Just in the last year, we had gene therapies approved, we had cell-based therapies approved, we had RNAi approved as actual marketable products for the first time, so all of a sudden, you have this huge window opened up for you in the different types of approa…”

“I believe that the future will definitely involve a strong component of user pays, so I think the products that are developed will have to be in indications that the patients are actually willing to pay for”

“Biotechs are different because you can't really change the outcome of the science. Like the science is the science. So either it works or it doesn't work. And that's very different than software where you can actually, you know, pivot around and keep developin…”

“So it's very rare that startups build a successful moat using patents. This happens much more in, like, biotech”